Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | GUCY1B2 | O75343 | 2/20 | 0.31 |
| ▸ | GUCY1A2 | P33402 | 2/20 | 0.31 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.31 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803195 | 1.00 | MMP1 (0.34) | MMP1MMP2MMP9MMP12IDO1 | |
| SCHEMBL4807822 | 0.82 | IDO1 (0.44) | IDO1KMT2AALDH1A1L3MBTL1ATM | |
| SCHEMBL4807830 | 0.82 | IDO1 (0.44) | IDO1KMT2AALDH1A1L3MBTL1ATM | |
| SCHEMBL4798572 | 0.78 | CTSL (0.33) | — | |
| SCHEMBL4798577 | 0.78 | CTSL (0.33) | — | |
| SCHEMBL12936611 | 0.76 | MMP1 (0.37) | MMP1MMP2MMP9MMP12IDO1 | |
| SCHEMBL4805610 | 0.75 | SLC1A2 (0.41) | MMP1MMP2MMP9MMP12KMT2A | |
| SCHEMBL4807936 | 0.74 | SLC1A3 (0.45) | IDO1KMT2AALDH1A1MEN1 | |
| SCHEMBL4807929 | 0.74 | SLC1A3 (0.45) | IDO1KMT2AALDH1A1MEN1 | |
| SCHEMBL5172388 | 0.71 | MMP1 (0.41) | MMP1MMP2MMP9MMP12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446125-B2 | Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2008-11-04 | — | — | US | disclosed |
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | UNIVERSIDAD DEL PAIS VASCO (ES) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211630-A1 | Novel synthetic compounds, processes of manufacture and uses in the treatment of integrin-mediated disorders | ITGB5, ITGA5, ITGAV | MMP1 1884/4885MMP2 2533/4885MMP9 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.